勵晶太平洋(00575.HK)將獲萬邦醫藥支付里程碑款項至少288萬美元
勵晶太平洋(00575.HK)公布,獲復星醫藥(02196.HK)旗下江蘇萬邦生化醫藥通知,產品Senstend已於2月5日取得藥品審評中心之臨床試驗審批,為產品的重要里程碑,萬邦醫藥因此須向公司支付預扣稅前款項 320萬美元,或預扣稅後288萬美元。
勵晶太平洋表示,現時將盡全力展開隨機化臨床試驗工作,該計劃將於4月至5月份開始,預計12個月內完成,江蘇萬邦醫藥已委聘一間合同研究機構進行第三期雙盲多中心隨機化臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.